Skip to main content
Premium Trial:

Request an Annual Quote

HPCGG Completes Evaluation of AutoGenomics' Warfarin Panel

NEW YORK (GenomeWeb News) – AutoGenomics said last week that the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics has completed an evaluation of its CYP450 2C9-VKORC1 panel for warfarin dosing.
The company submitted the assay to the US Food and Drug Administration for 510(k) approval last December. The test runs on AutoGenomics’ Infiniti platform, which the FDA cleared for multiplex testing earlier this year.
The Infiniti 2C9-VKORC1 panel “has the potential to optimize warfarin dosing and lower the risk of bleeding complications," said Raju Kucherlapati, HPCGG scientific director, in a statement.
HPCGG is leading the "CReating an Optimal Warfarin Nomogram," or CROWN, trial, a prospective study that is using genetic tests to determine optimal warfarin dosing. The CROWN trial is scheduled to be completed by the end of the year. Further information on the study is available here.
Last week, the FDA updated warfarin’s label to include information on how variations in the CYP2C9 and VKORC1 genes may affect patient response to the anticoagulant.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.